Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 5/6 |
Past Performance | 3/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
MF6 Stock Overview
MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland.
Rewards
Risk Analysis
+ 3 more risks
MagForce Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.03 |
52 Week High | €4.15 |
52 Week Low | €1.74 |
Beta | 2.1 |
1 Month Change | -22.52% |
3 Month Change | -15.42% |
1 Year Change | -49.38% |
3 Year Change | -57.22% |
5 Year Change | -74.41% |
Change since IPO | -96.83% |
Recent News & Updates
Shareholder Returns
MF6 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | -0.5% | 5.5% | 1.2% |
1Y | -49.4% | 0.2% | -12.2% |
Return vs Industry: MF6 underperformed the German Medical Equipment industry which returned 0.2% over the past year.
Return vs Market: MF6 underperformed the German Market which returned -12.2% over the past year.
Price Volatility
MF6 volatility | |
---|---|
MF6 Average Weekly Movement | 12.8% |
Medical Equipment Industry Average Movement | 6.5% |
Market Average Movement | 6.4% |
10% most volatile stocks in DE Market | 10.7% |
10% least volatile stocks in DE Market | 3.5% |
Stable Share Price: MF6 is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: MF6's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 34 | Ben Lipps | https://www.magforce.com |
MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of solid tumors; NanoPlan, a simulation software that helps the treating physicians to define the NanoTherm therapy schedule according to the distribution of the NanoTherm depots in the tumor; and NanoActivator, a magnetic field applicator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
MagForce Fundamentals Summary
MF6 fundamental statistics | |
---|---|
Market Cap | €59.81m |
Earnings (TTM) | €14.57m |
Revenue (TTM) | €1.27m |
4.1x
P/E Ratio47.1x
P/S RatioIs MF6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MF6 income statement (TTM) | |
---|---|
Revenue | €1.27m |
Cost of Revenue | €808.15k |
Gross Profit | €461.21k |
Other Expenses | -€14.11m |
Earnings | €14.57m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Jun 30, 2022
Earnings per share (EPS) | 0.49 |
Gross Margin | 36.33% |
Net Profit Margin | 1,147.78% |
Debt/Equity Ratio | 86.3% |
How did MF6 perform over the long term?
See historical performance and comparisonValuation
Is MagForce undervalued compared to its fair value and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MF6 (€2.03) is trading below our estimate of fair value (€7.84)
Significantly Below Fair Value: MF6 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MF6 is good value based on its PE Ratio (4.1x) compared to the German Medical Equipment industry average (31.2x).
PE vs Market: MF6 is good value based on its PE Ratio (4.1x) compared to the German market (17.3x).
Price to Earnings Growth Ratio
PEG Ratio: MF6 is good value based on its PEG Ratio (0.1x)
Price to Book Ratio
PB vs Industry: MF6 is good value based on its PB Ratio (1.9x) compared to the DE Medical Equipment industry average (2.9x).
Future Growth
How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
5/6Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
50.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MF6's forecast earnings growth (50.3% per year) is above the savings rate (-0.05%).
Earnings vs Market: MF6's earnings (50.3% per year) are forecast to grow faster than the German market (7.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MF6's revenue (45.8% per year) is forecast to grow faster than the German market (4.9% per year).
High Growth Revenue: MF6's revenue (45.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MF6's Return on Equity is forecast to be low in 3 years time (3.2%).
Past Performance
How has MagForce performed over the past 5 years?
Past Performance Score
3/6Past Performance Score 3/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
45.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MF6 has a large one-off gain of €24.5M impacting its June 30 2021 financial results.
Growing Profit Margin: MF6 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MF6 has become profitable over the past 5 years, growing earnings by 45.2% per year.
Accelerating Growth: MF6 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MF6 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16%).
Return on Equity
High ROE: MF6's Return on Equity (47.2%) is considered outstanding.
Financial Health
How is MagForce's financial position?
Financial Health Score
0/6Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: MF6's short term assets (€2.1M) do not cover its short term liabilities (€11.9M).
Long Term Liabilities: MF6's short term assets (€2.1M) do not cover its long term liabilities (€21.6M).
Debt to Equity History and Analysis
Debt Level: MF6's net debt to equity ratio (84.1%) is considered high.
Reducing Debt: Insufficient data to determine if MF6's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: Insufficient data to determine if MF6's debt is well covered by operating cash flow.
Interest Coverage: Insufficient data to determine if MF6's interest payments on its debt are well covered by EBIT.
Balance Sheet
Dividend
What is MagForce current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MF6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MF6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MF6's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MF6's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MF6 has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
9.1yrs
Average management tenure
CEO
Ben Lipps (81 yo)
8.67yrs
Tenure
Dr. Benjamin J. Lipps, also known as Ben, serves as Director and Chief Executive Officer at MagForce USA, Inc. He has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG si...
Leadership Team
Experienced Management: MF6's management team is seasoned and experienced (9.1 years average tenure).
Board Members
Experienced Board: MF6's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Top Shareholders
Company Information
MagForce AG's employee growth, exchange listings and data sources
Key Information
- Name: MagForce AG
- Ticker: MF6
- Exchange: XTRA
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €59.809m
- Shares outstanding: 29.46m
- Website: https://www.magforce.com
Number of Employees
Location
- MagForce AG
- Max-Planck-Strasse 3
- Berlin
- Berlin
- 12489
- Germany
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/16 00:00 |
End of Day Share Price | 2022/05/16 00:00 |
Earnings | 2021/06/30 |
Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.